Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORTOCI: Tocilizumab add-on in Giant Cell Arteritis
NCT01910038Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Nov 2013
- Primary completion
- Dec 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in giant cell arteritis (GCA), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Nov 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT01910038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01910038.